2010 Interpretive Criteria for Neisseria gonorrhoeae Susceptibility Testing
The following are zone diameter interpretive standards and equivalent minimal inhibitory concentration (MIC) breakpoints* for Neisseria gonorrhoeae according to the National Committee for Clinical Laboratory Standards (Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement, January 2010, M100-S20 Vol 30 No 1:
*At this time, no interpretive criteria exists for Azithromycin and Levofloxacin
| Antimicrobial Agent | Zone
Diameter (nearest whole mm) |
Equivalent
MIC Breakpoints (µg/mL) |
|||
|---|---|---|---|---|---|
| R | I | S | R | S | |
Penicillins |
|||||
| Penicillin | <=26 | 27-46 | >=47 | >=2 | <=0.06 |
Cephems (Parenteral) |
|||||
| Cefotaxime | - | - | >=31 | - | <=0.5 |
| Ceftizoxime | - | - | >=38 | - | <=0.5 |
| Ceftriaxone | - | - | >=35 | - | <=0.25 |
Cefmetazole |
<=27 | 28-32 | >=33 | >=8 | <=2 |
| Cefotetan | <=19 | 20-25 | >=26 | >=8 | <=2 |
| Cefoxitin | <=23 | 24-27 | >=28 | >=8 | <=2 |
| Cefuroxime sodium (parenteral) | <=25 | 26-30 | >=31 | >=4 | <=1 |
|
Cefepime |
- | - | >=31 | - | <=0.5 |
|
Ceftazidime |
- | - | >=31 | - | <=0.5 |
|
Cephems (Oral) |
|||||
| Cefixime | - | - | >=31 | - | <=0.25 |
|
Cefpodoxime |
- | - | >=29 | - | <=0.5 |
|
Cefetamet |
- | - | >=29 | - | <=0.5 |
|
Tetracyclines |
|||||
|
Tetracycline |
<=30 | 31-37 | >=38 | >=2 | <=0.25 |
|
Fluoroquinolones |
|||||
Ciprofloxacin |
<=27 | 28-40 | >=41 | >=1 | <=0.06 |
| Gatifloxacin | <=33 | 34-37 | >=38 | >=0.5 | <=0.12 |
| Ofloxacin | <=24 | 25-30 | >=31 | >=2 | <=0.25 |
|
Enoxacin |
<=31 | 32-35 | >=36 | >=2 | <=0.5 |
|
Grepafloxacin |
<=27 | 28-36 | >=37 | >=1 | <=0.06 |
|
Lomefloxacin |
<=26 | 27-37 | >=38 | >=2 | <=0.12 |
|
Trovafloxacin |
- | - | >=34 | - | <=0.25 |
|
Fleroxacin |
<=28 | 29-34 | >=35 | >=1 | <=0.25 |
|
Aminocyclitols |
|||||
|
Spectinomycin |
<=14 | 15-17 | >=18 | >=128 | <=32 |
